Estee Lauder
EL
94.45
+1.09
+1.17%
Estee Lauder
US · EL
#619 by market cap
Listed 1970
94.45
+1.09
+1.17%
Live - 5344 symbols - heartbeat 194s ago
· 2026-10-08 08:25
Pre-market
94.45
0.00%
After-hours
94.45
0.00%
Overnight
94.00
-0.48%
- Market cap
- 34.22B
- P/E (TTM)i
- 188.90
- P/Bi
- 8.99
- EPSi
- 0.50
- Div yieldi
- 1.48%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on EL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.22, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.05% YoY
Margins
- Gross margin
- 75.50%
- Operating margin
- 11.14%
- Net margin
- 1.21%
Key ratios & quality
- Enterprise valuei
- 38.43B
- Altman Z-Scorei
- 3.22
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.86B | 14.29B | 16.22B | 17.74B | 15.91B | 15.61B | 14.33B | 15.05B |
| Gross profit | 11.48B | 10.74B | 12.38B | 13.43B | 11.35B | 11.18B | 10.60B | 11.36B |
| Selling & admin expenses | 8.86B | 8.64B | 9.37B | 9.89B | 9.58B | 9.62B | 9.46B | 9.69B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.62B | 2.11B | 3.01B | 3.54B | 1.77B | 1.56B | 1.14B | 1.68B |
| Pretax profit | 2.31B | 1.05B | 3.33B | 3.04B | 1.40B | 772.00M | -1.04B | 517.00M |
| Tax | 513.00M | 350.00M | 456.00M | 628.00M | 387.00M | 363.00M | 93.00M | 335.00M |
| Net profit | 1.79B | 696.00M | 2.88B | 2.41B | 1.01B | 409.00M | -1.13B | 182.00M |
| Basic EPS | 5 | 2 | 8 | 7 | 3 | 1 | -3 | 1 |
| Diluted EPS | 4.82 | 1.86 | 7.79 | 6.55 | 2.79 | 1.08 | -3.15 | 0.50 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.55B | 3.41B | 3.48B | 4.23B | 3.71B | 3.63B |
| Gross profit | 2.66B | 2.46B | 2.55B | 3.24B | 2.84B | 2.74B |
| Selling & admin expenses | 2.26B | 2.32B | 2.30B | 2.63B | 2.28B | 2.48B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 403.00M | 141.00M | 258.00M | 608.00M | 557.00M | 254.00M |
| Pretax profit | 241.00M | -451.00M | 109.00M | 333.00M | 179.00M | -104.00M |
| Tax | 82.00M | 95.00M | 62.00M | 171.00M | 90.00M | 12.00M |
| Net profit | 159.00M | -546.00M | 47.00M | 162.00M | 89.00M | -116.00M |
| Basic EPS | 0 | -2 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.44 | -1.51 | 0.13 | 0.44 | 0.24 | -0.32 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 7.21B | 8.89B | 9.77B | 9.30B | 9.14B | 7.92B | 7.07B | 7.61B |
| Cash & ST investments | 2.99B | 5.02B | 4.96B | 3.96B | 4.03B | 3.40B | 2.92B | 3.50B |
| Inventory | 2.01B | 2.06B | 2.51B | 2.92B | 2.98B | 2.18B | 2.07B | 2.00B |
| Total assets | 13.16B | 17.78B | 21.97B | 20.91B | 23.42B | 21.68B | 19.89B | 19.76B |
| Total current liabilities | 4.61B | 5.18B | 5.30B | 5.82B | 6.24B | 5.70B | 5.44B | 6.23B |
| Short-term debt | 516.00M | 1.60B | 411.00M | 633.00M | 1.35B | 858.00M | 409.00M | 902.00M |
| Long-term debt | 2.90B | 4.91B | 5.54B | 5.14B | 7.12B | 7.27B | 7.31B | 6.80B |
| Total liabilities | 8,745,000,000.00 | 13,819,000,000.00 | 15,023,000,000.00 | 14,478,000,000.00 | 16,998,000,000.00 | 16,363,000,000.00 | 16,027,000,000.00 | 15,956,000,000.00 |
| Total equity | 4.41B | 3.96B | 6.95B | 6.43B | 6.42B | 5.31B | 3.87B | 3.81B |
| Retained earnings | 9.98B | 10.13B | 12.24B | 13.91B | 13.99B | 13.43B | 11.67B | 11.34B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 7.02B | 7.07B | 6.71B | 7.16B | 7.50B | 7.61B |
| Cash & ST investments | 2.63B | 2.92B | 2.22B | 3.08B | 3.13B | 3.50B |
| Inventory | 1.96B | 2.07B | 2.06B | 1.90B | 1.92B | 2.00B |
| Total assets | 19.89B | 19.89B | 19.33B | 19.63B | 19.66B | 19.76B |
| Total current liabilities | 4.96B | 5.44B | 5.08B | 5.27B | 5.91B | 6.23B |
| Short-term debt | 402.00M | 409.00M | 418.00M | 416.00M | 903.00M | 902.00M |
| Long-term debt | 7.30B | 7.31B | 7.32B | 7.32B | 6.81B | 6.80B |
| Total liabilities | 15,541,000,000.00 | 16,027,000,000.00 | 15,439,000,000.00 | 15,603,000,000.00 | 15,671,000,000.00 | 15,956,000,000.00 |
| Total equity | 4.35B | 3.87B | 3.89B | 4.03B | 3.99B | 3.81B |
| Retained earnings | 12.34B | 11.67B | 11.59B | 11.62B | 11.59B | 11.34B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.52B | 2.28B | 3.63B | 3.04B | 1.73B | 2.36B | 1.27B | 1.77B |
| Depreciation & amortization | 557.00M | 611.00M | 651.00M | 727.00M | 744.00M | 825.00M | 829.00M | 796.00M |
| Free cash flow | 1.77B | 1.66B | 2.99B | 2.00B | -1.56B | 1.44B | 670.00M | 1.32B |
| Dividends paid | -609.00M | -503.00M | -753.00M | -840.00M | -925.00M | -947.00M | -618.00M | -508.00M |
| Stock buybacks / issuance | -1.56B | -893.00M | -733.00M | -2.31B | -271.00M | -35.00M | -35.00M | -70.00M |
| Ending cash balance | 2.99B | 5.02B | 4.96B | 3.96B | 4.03B | 3.40B | 2.92B | 3.50B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 284.00M | 601.00M | -340.00M | 1.13B | 412.00M | 576.00M |
| Depreciation & amortization | 204.00M | 210.00M | 200.00M | 197.00M | 201.00M | 198.00M |
| Free cash flow | 162.00M | 394.00M | -436.00M | 1.02B | 310.00M | 425.00M |
| Dividends paid | -126.00M | -126.00M | -127.00M | -128.00M | -126.00M | -127.00M |
| Stock buybacks / issuance | 0 | 0 | -9.00M | -58.00M | -3.00M | 0 |
| Ending cash balance | 2.63B | 2.92B | 2.22B | 3.08B | 3.13B | 3.50B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 39.34 | 16.44 | 57.45 | 41.04 | 18.00 | 7.16 | -24.69 | 4.75 |
| ROA %i | 13.88 | 4.42 | 14.44 | 11.15 | 4.54 | 1.73 | -5.45 | 0.92 |
| ROIC %i | 23.00 | 7.40 | 22.14 | 18.24 | 7.56 | 3.54 | -6.69 | 2.49 |
| 5-year avg ROE %i | 31.02 | 28.50 | 33.81 | 35.74 | 34.45 | 28.02 | 19.79 | 9.25 |
| EBIT margin %i | 16.42 | 8.44 | 21.61 | 18.06 | 10.38 | 7.37 | -4.77 | 5.65 |
| FCF / sales %i | 11.93 | 11.59 | 18.46 | 11.28 | -- | 9.23 | 4.68 | 8.74 |
| Current ratioi | 1.57 | 1.72 | 1.84 | 1.60 | 1.46 | 1.39 | 1.30 | 1.22 |
| Quick ratioi | 1.05 | 1.20 | 1.26 | 0.96 | 0.88 | 0.90 | 0.82 | 0.81 |
| Debt / assetsi | 25.93 | 49.43 | 36.86 | 36.56 | 43.43 | 45.33 | 47.59 | 46.79 |
| LT debt / equityi | 66.03 | 182.77 | 126.93 | 125.44 | 157.83 | 168.76 | 234.36 | 219.23 |
| Interest coveragei | 18.35 | 7.50 | 20.25 | 19.18 | 6.48 | 3.04 | -1.91 | 2.55 |
| Revenue CAGR (3Y) %i | 9.69 | 6.53 | 5.82 | 6.07 | 3.63 | -1.26 | -6.87 | -1.84 |
| Net income CAGR (3Y) %i | 16.98 | -18.19 | 37.33 | 10.22 | 13.72 | -48.59 | -- | -43.44 |
| FCF CAGR (3Y) %i | 11.94 | 8.82 | 15.70 | 4.10 | -- | -21.63 | -30.55 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -17.27 | -24.69 | -20.73 | -4.34 | -5.95 | 4.75 |
| ROA %i | -4.09 | -5.45 | -4.58 | -0.90 | -1.25 | 0.92 |
| ROIC %i | -4.75 | -6.69 | -5.28 | 0.00 | -0.74 | 2.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -3.44 | -4.77 | -2.77 | 3.94 | 3.45 | 5.65 |
| FCF / sales %i | 6.41 | 4.68 | 7.23 | 7.75 | 8.66 | 8.74 |
| Current ratioi | 1.41 | 1.30 | 1.32 | 1.36 | 1.27 | 1.22 |
| Quick ratioi | 0.89 | 0.82 | 0.81 | 0.90 | 0.82 | 0.81 |
| Debt / assetsi | 47.18 | 47.59 | 48.75 | 47.83 | 47.29 | 46.79 |
| LT debt / equityi | 206.67 | 234.36 | 231.47 | 222.62 | 210.29 | 219.23 |
| Interest coveragei | -1.41 | -1.91 | -1.14 | 1.67 | 1.50 | 2.55 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Skin Care is the largest reported line at 48.76% of revenue, across 6 reported segments.
- Makeup follows at 28.41%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Skin Care48.76%
Makeup28.41%
Fragrance18.47%
Hair Care3.75%
Other category net sales0.68%
Region
All other countries48.97%
Mainland China26.11%
United States24.91%
Quote time 2026-10-08 08:25:52 · For reference only, not investment advice and not tailored to your situation.